{"schema_version":"secwatch.filing_event.v1","accession":"0000927066-26-000060","form_type":"8-K","ticker":"DVA","cik":"0000927066","company_name":"DAVITA INC.","filed_at":"2026-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.945422+00:00","generated_at":"2026-05-14T23:44:44.438741+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"DaVita Q1 2026 adj EPS $2.87 vs $2.00 YoY; revenue $3.416B, repurchased 3M shares","bullets":["GAAP and adjusted diluted EPS $2.87, up 44% YoY from $2.00; down sequentially from $3.40 in Q4 2025.","Consolidated revenue $3.416B; operating income $482M; operating cash flow $321M; free cash flow $140M.","Repurchased 3.0M shares at avg price $133.70 per share during Q1 2026.","CEO Javier Rodriguez highlighted clinical excellence and durable results; net income from continuing ops $198M."],"urls":{"canonical":"https://secwatch.observer/filing/0000927066-26-000060","json":"https://secwatch.observer/filing/0000927066-26-000060.json","markdown":"https://secwatch.observer/filing/0000927066-26-000060.md","text":"https://secwatch.observer/filing/0000927066-26-000060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/927066/000092706626000060/0000927066-26-000060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/927066/000092706626000060/dva-20260505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:44:44.438741+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e6e14d3791e71ea589c4f385de193f34bdd6422f","claim":"DAVITA INC. reported the quarter ended March 31, 2026 results: revenue $3.416 billion, net income $198 million, EPS $2.87.","evidence_excerpt":"strong financial performance, and this quarter is no exception.” Financial and operating highlights for the quarter and year ended March 31, 2026: • Consolidated revenues were $3.416 billion. • Operating income was $482 million. • Diluted earnings per share from continuing operations was $2.87. • Operating cash flow was $321 million and free cash flow was $140","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/927066/000092706626000060/0000927066-26-000060-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Revenue","value":"$3.416 billion"},{"label":"Net income","value":"$198 million"},{"label":"EPS","value":"$2.87"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}